MANAGEMENT

John F. Andrews

John F. Andrews

CEO & Director, Applied UV

John F. Andrews has over 30 years of senior leadership experience in telecom and technology companies, both public and private. He has been CEO of several public companies as well as started and founded companies from ground zero.

Full Bio

John F. Andrews has over 30 years of senior leadership experience in telecom and technology companies, both public and private. He has been CEO of several public companies as well as started and founded companies from ground zero. His experience includes leading three (3) companies to strategic exits (two (2) private and one (1) public), raising over one hundred (100) million dollars of public and private capital, managing numerous mergers and acquisitions, leading companies through explosive growth as well as rightsizing, and being recruited to turn around stalled companies. He recently was the CEO and Co-founder of Trinity IT Services LLC and CEO of TrekSecure LLC.   A seasoned executive, his experience also includes being Chairman and EVP of ShipXpress which GE acquired, being CEO of Giga (NASDAQ GIGA) where he led the company’s sale to Forrester Research (NASDAQ FORR) and being the CEO of e-Medsoft of which went public. His fortune 300 corporate experience includes being CIO and SVP of CSX Transportation at CSX (NASDAQ CSX) corporation managing thousands of employees. During his tenure at CSX, he was credited in achieving over five hundred (500) million dollars in operating expense reductions through his visionary and portfolio technology projects. As CIO he received several industry awards to include CIO of the year from Information Week and top industry visionary from Computerworld. While at CSX, Andrews also consulted with Sun Microsystems (NASDAQ SUNW) on the development of JAVA. Prior to CSX Andrews held executive positions with telecom giant GTE, to include division CIO, President Government Information Systems and President Healthcare Information Systems. Andrews has an MBA from the University of Puget-Sound, Seattle WA, and a BA, Business Administration and Finance from Whitworth University, Spokane WA.

Max Munn

Max Munn

President & Director, Applied UV & CEO, MunnWorks

Mr. Munn has held this position at Munn Works for over 20 years. Mr. Munn is also Co-chairman of Dieu Donne Inc., a not-for-profit and a leading, world recognized atelier wherein dimensional, handmade paper is utilized in the making of art.

Full Bio
Mr. Munn attended MIT from 1961-1966, majored in chemistry and architecture; and received a Bachelors of Architecture degree. Mr. Munn also attended Columbia University for post graduate studies from 1966-1968, working toward a Ph.D. in architectural history.
John Hayman III

John Hayman III

Senior Vice President of Operations

Mr. Hayman served as Kes Science’s President and CEO for 18 years leading the company’s growth, R&D, and new product development. Prior to Kes, Mr. Hayman was an accountant where he earned his COA Certification and ended his tenure as a Certified Public Account with KMPG.

Mike Riccio

Mike Riccio

Chief Financial Officer

Mr. Riccio has more than 25 years of experience in financial leadership roles with a proven track record developed while working in complex financial organizations.

Before joining Applied UV, Mr. Riccio served as Chief Financial Officer & Treasurer of Panasonic Corporation of North America.

Full Bio

Mr. Riccio joins Applied UV with broad experience in corporate and operational finance, most recently as Chief Financial Officer & Treasurer of Panasonic Corporation of North America, leading the finance organization that supports the principal North American subsidiary of Osaka, Japan-based Panasonic Corporation. Throughout his career at the Panasonic subsidiary, he demonstrated a track record as a results-oriented leader with a strong record of improving financial performance across a variety of sectors, including consumer, systems and solutions, and industry. Working with other executives, Mr. Riccio was part of the team that defined and implemented strategies driving significant growth of Panasonic North America revenue.

He joined Panasonic in October 1986 from Sealed Air Corporation, where he  was the Corporate Accounting Manager. Prior to Sealed Air, Mr. Riccio was a Senior Auditor at CohnReznick. Mr. Riccio is a Certified Public Accountant (CPA) and holds a B.A. in accounting from Rutgers University and an MBA in finance from Rutgers Business School.

Joel Kanter

Joel Kanter

Chairman

Mr. Kanter serves as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999, Mr. Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (Nasdaq: WNUT).

Full Bio
Walnut Financial’s primary business focus was the provision of various forms of financing to small business including equity financing to start-up and early stage development companies, bridge financing to small and medium-sized companies, and later stage institutional financing to mature enterprises. Tower Hill Capital bought the Company in 1999 in a transaction valued at approximately $400 million.

From 1978 – 1980, Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.). In that position, Mr. Kanter provided support to Congressman Mikva with respect to activities related to his position on the House Judiciary Committee. In particular, Mr. Kanter was intimately involved in efforts to reform the Federal Criminal Code. Mikva subsequently became the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit, and then served as White House Counsel to President Clinton.

From 1980 – 1983, Mr. Kanter served as Special Assistant to the National Association of Attorneys General. In that position, he represented the interests of the State Attorneys General in Washington, D.C. in the criminal justice and environmental arenas.

Mr. Kanter serves on the Board of Directors of one currently public company, Magna-Labs, Inc., which was formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the boards of several private biotechnology companies.

Mr. Kanter is a National Association of Corporate Directors “Governance Fellow.” Mr. Kanter is a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and a former Trustee of the Union Institute & University, the Country’s first Online University.

Dr. Eugene A. Bauer, M.D.

Dr. Eugene A. Bauer, M.D.

Director

In 2010, Dr. Bauer co-founded Dermira, a publicly traded specialty biopharmaceutical company acquired by Eli Lilly and Company in 2020. Dr. Bauer served as Chief Medical Officer of Dermira, a wholly-owned subsidiary of Lilly, through March 2020.
Full Bio
Prior to founding Dermira, Dr. Bauer served as Director, President and Chief Medical Officer of Pelpin, Inc., a publicly traded specialty pharmaceutical company, from 2008 to 2010.

Dr. Bauer served as Chief Executive Officer of Neosil, Inc., a specialty pharmaceutical company, from 2004 to 2008, and he co-founded and served as a member of the board of directors at Connetics, a publicly traded specialty pharmaceutical company, from 1990 to 2006.

Prior to initiating his career in industry, Dr. Bauer served as Dean of Stanford University School of Medicine from 1995 to 2001 and as Chair of the Department of Dermatology at Stanford University School of Medicine from 1988 to 1995. Dr. Bauer is Professor Emeritus at Stanford University School of Medicine, a position he has held since 2002.

Dr. Bauer was a U.S. National Institutes of Health (“NIH”)-funded investigator for 25 years and has served on review groups and Councils for the NIH. Dr. Bauer has served on the boards of directors of a number of public and private companies, including Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., and Kadmon Holdings, Inc. He is member of numerous honorific societies, including the National Academy of Medicine. Dr. Bauer received his B.S. in medicine from Northwestern University and his M.D. from Northwestern University Medical School.

Alastair J. Clemow, Ph.D.

Alastair J. Clemow, Ph.D.

Director

Dr. Clemow currently serves as Chairman of Ensemble Orthopedics, an early-stage company developing an innovative pyrocarbon finger joint for the treatment for early state osteoarthritis. From 2010 to 2019, Dr. Clemow served as President and Chief Executive Officer of Regentis Biomaterials, a private company developing an innovative material for cartilage repair.
Full Bio
He also held positions of president and chief executive officer in a number of companies that he helped found, including Nexgen Spine, Inc., which developed an artificial spinal disc; Gelifex, Inc., which developed an innovative spinal nucleus replacement implant and which was acquired in 2004 by Synthes Spine, Inc.; and Minimally Invasive Surgical Technologies, Inc., which developed a novel series of implants for minimally invasive total knee replacement and which was acquired in 2005 by MAKO Surgical Corp.

From 2000 to 2004, Dr. Clemow served as Principal of Tanton Technologies, Inc., an organization that provided strategic and technical assessment of new medical device opportunities for large, mid-cap, and early-stage development companies.

From 1981 to 2000, Dr. Clemow held numerous positions with Johnson & Johnson, including Vice President of Worldwide Business Development for Ethicon Endo-Surgery, Inc.; Vice President of New Business Development for Johnson & Johnson Professional, Inc.; and Director of Research and Development of Johnson & Johnson Orthopedics. In those capacities, Dr. Clemow was responsible for acquiring or developing what today represents billions of dollars of Johnson & Johnson revenue.

Dr. Clemow serves or has served on the boards of numerous private and public companies including Aevi Genomics; Encore Medical; Echo Healthcare Acquisition Corp.; BioMedical Enterprises, Inc.; and Kinetic Muscles, Inc. He graduated from the University of Surrey with a Bachelor of Science Degree in metallurgy and Ph.D. in metallurgy and earned his MBA degree from Columbia University in New York.

Dallas C. Hack, M.D., M.P.H.

Dallas C. Hack, M.D., M.P.H.

Director

Dr. Hack is board certified in General Preventive Medicine and Public Health and a Fellow in the American College of Military Public Health. He directed trauma research for the military from 2008 to 2014, with responsibility for more than $2 billion in grant funding.

Full Bio
He served as Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. He held numerous military medical leadership positions including Commander of the NATO Headquarters Healthcare Facility, and Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. COL(R) Hack received numerous military awards including the Bronze Star, two Legion of Merit awards, and was inducted as a Distinguished Member of the Military Order of Medical Merit.

He has a BA from Andrews University (1972), an MPH from Johns Hopkins University (1995), a MD from Loma Linda University (1976), an MSS from the US Army War College (2004), and a CPE from the Certifying Commission in Medical Management (1997). He was recognized as the Distinguished Alumnus of the Year by Loma Linda University in May 2015. Dr. Hack has an appointment from the School of Medicine, University of Pittsburgh as Adjunct Professor of Neurosurgery and from Virginia Commonwealth University as an Associate Clinical Professor, Department of Physical Medicine and Rehabilitation. After retiring from 28 years of military service in 2015, Dr. Hack has worked with numerous biotechs and non-profits to advance medical research and transition the progress to improved clinical practice.

Eugene E. Burleson

Eugene E. Burleson

Director

Eugene E. Burleson is a private investor and was Chairman of PET DRx Corporation from June 2005 to July 1, 2010, and its Chief Executive Officer from October 2008 until its acquisition by VCA Antech in July 2010. Mr. Burleson was a director of HealthMont Inc. from September 2000 until its acquisition by SunLink in October 2003.

Full Bio
Mr. Burleson served as Chairman of the Board of Directors of Mariner Post-Acute Network, Inc. from January 2000 to June 2002. Mr. Burleson also served as Chairman of the Board of Directors of Alterra Healthcare Inc. a developer and operator of assisted living facilities and is on the Board of Deckers Outdoor Corporation Inc. Mr. Burleson served as Chairman of the Board of GranCare Inc. from October 1989 to November 1997.

Additionally, Mr. Burleson served as President and Chief Executive Officer of GranCare Inc. from December 1990 to February 1997. Upon completion of the merger of GranCare’s pharmacy operations with Vitalink Pharmacy Services Inc. in February 1997, he became Chief Executive Officer and a Director of Vitalink Pharmacy Services Inc. Mr. Burleson resigned as Chief Executive Officer and Director of Vitalink Pharmacy Services in August 1997.

From June 1986 to March 1989, Mr. Burleson served as President, Chief Operating Officer and a Director of American Medical International Inc. (“AMI”), an owner and operator of acute care hospitals. Based in London from May 1981 to June 1986, Mr. Burleson served as Managing Director of AMI’s international operations. Mr. Burleson received his early management training at Eastman Kodak from 1963 to 1974. He graduated from East Tennessee State University with a Bachelor of Science Degree in accounting and earned an MBA degree in 1972.

John F. Andrews

John F. Andrews

CEO & Director, Applied UV & CEO, MunnWorks

John F. Andrews has over 30 years of senior leadership experience in telecom and technology companies, both public and private. He has been CEO of several public companies as well as started and founded companies from ground zero.

Full Bio

John F. Andrews has over 30 years of senior leadership experience in telecom and technology companies, both public and private. He has been CEO of several public companies as well as started and founded companies from ground zero. His experience includes leading three (3) companies to strategic exits (two (2) private and one (1) public), raising over one hundred (100) million dollars of public and private capital, managing numerous mergers and acquisitions, leading companies through explosive growth as well as rightsizing, and being recruited to turn around stalled companies. He recently was the CEO and Co-founder of Trinity IT Services LLC and CEO of TrekSecure LLC.   A seasoned executive, his experience also includes being Chairman and EVP of ShipXpress which GE acquired, being CEO of Giga (NASDAQ GIGA) where he led the company’s sale to Forrester Research (NASDAQ FORR) and being the CEO of e-Medsoft of which went public. His fortune 300 corporate experience includes being CIO and SVP of CSX Transportation at CSX (NASDAQ CSX) corporation managing thousands of employees. During his tenure at CSX, he was credited in achieving over five hundred (500) million dollars in operating expense reductions through his visionary and portfolio technology projects. As CIO he received several industry awards to include CIO of the year from Information Week and top industry visionary from Computerworld. While at CSX, Andrews also consulted with Sun Microsystems (NASDAQ SUNW) on the development of JAVA. Prior to CSX Andrews held executive positions with telecom giant GTE, to include division CIO, President Government Information Systems and President Healthcare Information Systems. Andrews has an MBA from the University of Puget-Sound, Seattle WA, and a BA, Business Administration and Finance from Whitworth University, Spokane WA.

Max Munn

Max Munn

President & Director, Applied UV & CEO, MunnWorks

Mr. Munn has held this position at Munn Works for over 20 years. Mr. Munn is also Co-chairman of Dieu Donne Inc., a not-for-profit and a leading, world recognized atelier wherein dimensional, handmade paper is utilized in the making of art.

Full Bio

Mr. Munn attended MIT from 1961-1966, majored in chemistry and architecture; and received a Bachelors of Architecture degree. Mr. Munn also attended Columbia University for post graduate studies from 1966-1968, working toward a Ph.D. in architectural history.

John Hayman III

John Hayman III

Interim Chief Operating officer

Mr. Hayman served as Kes Science’s President and CEO for 18 years leading the company’s growth, R&D, and new product development. Prior to Kes, Mr. Hayman was an accountant where he earned his COA Certification and ended his tenure as a Certified Public Account with KMPG.

Mike Riccio

Mike Riccio

Chief Financial Officer

Mr. Riccio has more than 25 years of experience in financial leadership roles with a proven track record developed while working in complex financial organizations.

Before joining Applied UV, Mr. Riccio served as Chief Financial Officer & Treasurer of Panasonic Corporation of North America.

Full Bio

Mr. Riccio joins Applied UV with broad experience in corporate and operational finance, most recently as Chief Financial Officer & Treasurer of Panasonic Corporation of North America, leading the finance organization that supports the principal North American subsidiary of Osaka, Japan-based Panasonic Corporation. Throughout his career at the Panasonic subsidiary, he demonstrated a track record as a results-oriented leader with a strong record of improving financial performance across a variety of sectors, including consumer, systems and solutions, and industry. Working with other executives, Mr. Riccio was part of the team that defined and implemented strategies driving significant growth of Panasonic North America revenue.

He joined Panasonic in October 1986 from Sealed Air Corporation, where he  was the Corporate Accounting Manager. Prior to Sealed Air, Mr. Riccio was a Senior Auditor at CohnReznick. Mr. Riccio is a Certified Public Accountant (CPA) and holds a B.A. in accounting from Rutgers University and an MBA in finance from Rutgers Business School.

Joel Kanter

Joel Kanter

Chairman

Mr. Kanter serves as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999, Mr. Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (Nasdaq: WNUT).

Full Bio
Walnut Financial’s primary business focus was the provision of various forms of financing to small business including equity financing to start-up and early stage development companies, bridge financing to small and medium-sized companies, and later stage institutional financing to mature enterprises. Tower Hill Capital bought the Company in 1999 in a transaction valued at approximately $400 million.

From 1978 – 1980, Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.). In that position, Mr. Kanter provided support to Congressman Mikva with respect to activities related to his position on the House Judiciary Committee. In particular, Mr. Kanter was intimately involved in efforts to reform the Federal Criminal Code. Mikva subsequently became the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit, and then served as White House Counsel to President Clinton.

From 1980 – 1983, Mr. Kanter served as Special Assistant to the National Association of Attorneys General. In that position, he represented the interests of the State Attorneys General in Washington, D.C. in the criminal justice and environmental arenas.

Mr. Kanter serves on the Board of Directors of one currently public company, Magna-Labs, Inc., which was formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the boards of several private biotechnology companies.

Mr. Kanter is a National Association of Corporate Directors “Governance Fellow.” Mr. Kanter is a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and a former Trustee of the Union Institute & University, the Country’s first Online University.

Dr. Eugene A. Bauer, M.D.

Dr. Eugene A. Bauer, M.D.

Director

In 2010, Dr. Bauer co-founded Dermira, a publicly traded specialty biopharmaceutical company acquired by Eli Lilly and Company in 2020. Dr. Bauer served as Chief Medical Officer of Dermira, a wholly-owned subsidiary of Lilly, through March 2020.
Full Bio
Prior to founding Dermira, Dr. Bauer served as Director, President and Chief Medical Officer of Pelpin, Inc., a publicly traded specialty pharmaceutical company, from 2008 to 2010.

Dr. Bauer served as Chief Executive Officer of Neosil, Inc., a specialty pharmaceutical company, from 2004 to 2008, and he co-founded and served as a member of the board of directors at Connetics, a publicly traded specialty pharmaceutical company, from 1990 to 2006.

Prior to initiating his career in industry, Dr. Bauer served as Dean of Stanford University School of Medicine from 1995 to 2001 and as Chair of the Department of Dermatology at Stanford University School of Medicine from 1988 to 1995. Dr. Bauer is Professor Emeritus at Stanford University School of Medicine, a position he has held since 2002.

Dr. Bauer was a U.S. National Institutes of Health (“NIH”)-funded investigator for 25 years and has served on review groups and Councils for the NIH. Dr. Bauer has served on the boards of directors of a number of public and private companies, including Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., and Kadmon Holdings, Inc. He is member of numerous honorific societies, including the National Academy of Medicine. Dr. Bauer received his B.S. in medicine from Northwestern University and his M.D. from Northwestern University Medical School.

Alastair J. Clemow, Ph.D.

Alastair J. Clemow, Ph.D.

Director

Dr. Clemow currently serves as Chairman of Ensemble Orthopedics, an early-stage company developing an innovative pyrocarbon finger joint for the treatment for early state osteoarthritis. From 2010 to 2019, Dr. Clemow served as President and Chief Executive Officer of Regentis Biomaterials, a private company developing an innovative material for cartilage repair.
Full Bio
He also held positions of president and chief executive officer in a number of companies that he helped found, including Nexgen Spine, Inc., which developed an artificial spinal disc; Gelifex, Inc., which developed an innovative spinal nucleus replacement implant and which was acquired in 2004 by Synthes Spine, Inc.; and Minimally Invasive Surgical Technologies, Inc., which developed a novel series of implants for minimally invasive total knee replacement and which was acquired in 2005 by MAKO Surgical Corp.

From 2000 to 2004, Dr. Clemow served as Principal of Tanton Technologies, Inc., an organization that provided strategic and technical assessment of new medical device opportunities for large, mid-cap, and early-stage development companies.

From 1981 to 2000, Dr. Clemow held numerous positions with Johnson & Johnson, including Vice President of Worldwide Business Development for Ethicon Endo-Surgery, Inc.; Vice President of New Business Development for Johnson & Johnson Professional, Inc.; and Director of Research and Development of Johnson & Johnson Orthopedics. In those capacities, Dr. Clemow was responsible for acquiring or developing what today represents billions of dollars of Johnson & Johnson revenue.

Dr. Clemow serves or has served on the boards of numerous private and public companies including Aevi Genomics; Encore Medical; Echo Healthcare Acquisition Corp.; BioMedical Enterprises, Inc.; and Kinetic Muscles, Inc. He graduated from the University of Surrey with a Bachelor of Science Degree in metallurgy and Ph.D. in metallurgy and earned his MBA degree from Columbia University in New York.

Dallas C. Hack, M.D., M.P.H.

Dallas C. Hack, M.D., M.P.H.

Director

Dr. Hack is board certified in General Preventive Medicine and Public Health and a Fellow in the American College of Military Public Health. He directed trauma research for the military from 2008 to 2014, with responsibility for more than $2 billion in grant funding.

Full Bio
He served as Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. He held numerous military medical leadership positions including Commander of the NATO Headquarters Healthcare Facility, and Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. COL(R) Hack received numerous military awards including the Bronze Star, two Legion of Merit awards, and was inducted as a Distinguished Member of the Military Order of Medical Merit.

He has a BA from Andrews University (1972), an MPH from Johns Hopkins University (1995), a MD from Loma Linda University (1976), an MSS from the US Army War College (2004), and a CPE from the Certifying Commission in Medical Management (1997). He was recognized as the Distinguished Alumnus of the Year by Loma Linda University in May 2015. Dr. Hack has an appointment from the School of Medicine, University of Pittsburgh as Adjunct Professor of Neurosurgery and from Virginia Commonwealth University as an Associate Clinical Professor, Department of Physical Medicine and Rehabilitation. After retiring from 28 years of military service in 2015, Dr. Hack has worked with numerous biotechs and non-profits to advance medical research and transition the progress to improved clinical practice.

Eugene E. Burleson

Eugene E. Burleson

Director

Eugene E. Burleson is a private investor and was Chairman of PET DRx Corporation from June 2005 to July 1, 2010, and its Chief Executive Officer from October 2008 until its acquisition by VCA Antech in July 2010. Mr. Burleson was a director of HealthMont Inc. from September 2000 until its acquisition by SunLink in October 2003.

Full Bio
Mr. Burleson served as Chairman of the Board of Directors of Mariner Post-Acute Network, Inc. from January 2000 to June 2002. Mr. Burleson also served as Chairman of the Board of Directors of Alterra Healthcare Inc. a developer and operator of assisted living facilities and is on the Board of Deckers Outdoor Corporation Inc. Mr. Burleson served as Chairman of the Board of GranCare Inc. from October 1989 to November 1997.

Additionally, Mr. Burleson served as President and Chief Executive Officer of GranCare Inc. from December 1990 to February 1997. Upon completion of the merger of GranCare’s pharmacy operations with Vitalink Pharmacy Services Inc. in February 1997, he became Chief Executive Officer and a Director of Vitalink Pharmacy Services Inc. Mr. Burleson resigned as Chief Executive Officer and Director of Vitalink Pharmacy Services in August 1997.

From June 1986 to March 1989, Mr. Burleson served as President, Chief Operating Officer and a Director of American Medical International Inc. (“AMI”), an owner and operator of acute care hospitals. Based in London from May 1981 to June 1986, Mr. Burleson served as Managing Director of AMI’s international operations. Mr. Burleson received his early management training at Eastman Kodak from 1963 to 1974. He graduated from East Tennessee State University with a Bachelor of Science Degree in accounting and earned an MBA degree in 1972.